Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Zocor debuts

This article was originally published in The Tan Sheet

Executive Summary

McNeil Europe will sell Zocor Heart-Pro over the counter at a price of ?12.99 ($23.61) for a 28-day supply following the product's UK launch July 29, with plans to expand into other European markets. The UK Department of Health approved the switch from prescription-only to pharmacy status in May (1"The Tan Sheet" May 17, 2004, p. 5)...

You may also be interested in...



PAGB Unveils Guidelines On Pharmacist Training Programs For OTCs

The Proprietary Association of Great Britain's guidance on creating pharmacist-focused training materials for new pharmacy-status products arrives on the heels of the first nonprescription statin launch in the UK

Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement

Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel